The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Subscribe To Our Newsletter & Stay Updated
